Menstruation
PMS & PMDD — References & further reading
References
1 Ginsburg, K., & Dinsay, R. 2000. Premenstrual Syndrome. In: Ransom, S., ed. Practical Strategies in Obstetrics and Gynecology, (684–694). Philadelphia: W.B. Saunders Co.
Population Division, US Census Bureau. 06.14.2004. Annual estimates of the population by sex and five-year age groups for the United States: April 1, 2000 to July 1, 2003 (NC-EST2003-01). URL: http://www.census.gov/popest/national/asrh/NC-EST2003/NC-EST2003-01.pdf (accessed 01.22.2007).
2 Mishell, D. 2005. Epidemiology and etiology of premenstrual disorders. Managing the spectrum of premenstrual symptoms: A clinician’s guide (4–9). San Antonio: Dannemiller foundation/MedPro Communications, Inc.
3American Psychiatric Association. 2000. Diagnostic and Statistical Manual of Mental Disorders, 4th ed., text revision (771–774). Washington, DC: American Psychiatric Association.
4Sundstrom, P., et al. 2003. GABA receptors, progesterone and premenstrual dysphoric disorder. Arch. Women’s Ment. Health, 6(1), 23–41.
Rapkin, A., et al. Progesterone metabolite allopregnanolone in women with premenstrual syndrome. Obstet. Gynecol. 90(5), 709–714.
5 Akhondzadeh, S., et al. 2001b. Passionflower in the treatment of generalized anxiety: A pilot double-blind randomized controlled trial with oxazepam. J. Clin. Pharm. Ther., 26, 363–367.
Dhawan, K., et al. 2001. Anti-anxiety studies on extracts of Passiflora incarnata Linnaeus. J. Ethnopharmacol., 78 (2–3), 165–170.
Schellenberg, 2001. Treatment for the premenstrual syndrome with agnus castus fruit extract: Prospective, randomised, placebo controlled study. BMJ, 322, 134–137.
Berger, et al. 2000. Efficacy of Vitex agnus castus L. extract Ze 440 in patients with pre-menstrual syndrome (PMS). Arch. Gynecol. Obstet, 264, 150–153.
Lauritzen, et al. 1997. Treatment of premenstrual tension syndrome with Vitex agnus castus: Controlled double-blind study versus pyridoxine. Phytomedicine, 4, 183–189.
Smith, S., et al. 1987. Sex steroid effects on extrahypothalamic CNS. II. Progesterone, alone and in combination with estrogen, modulates cerebellar responses to amino acid neurotransmitters. Brain Res., 422 (1), 52–62.
Smith, S., et al. 1987. Progesterone alters GABA and glutamate responsiveness: A possible mechanism for its anxiolytic action. Brain Res., 400 (2), 353–359.
6 Johnson, S. 2001. The multifaceted and widespread pathology of magnesium deficiency. Med. Hypotheses, 56 (2), 163– 170.
Walker A., et al. 1998. Magnesium supplementation alleviates premenstrual symptoms of fluid retention. J. Women’s Health, 7 (9), 1157–1165.
7 Thys-Jacobs, S., et al. 1998. Calcium carbonate and the premenstrual syndrome: E ffects on premenstrual and menstrual symptoms. Premenstrual Syndrome Study Group. Am. J. Obstet. Gynecol, 179, 444– 452.
8 Rapkin, A. 2005. New approaches to treating premenstrual disorders. Managing the spectrum of premenstrual symptoms: A clinician’s guide.(15– 22). San Antonio: Dannemiller foundation/MedPro Communications, Inc
9 Steege J.,& Blumenthal, J. 1993. The effects of aerobic exercise on premenstrual symptoms in middle-aged women: A preliminary study. J. Psychosom. Res., 37 (2),127– 133.
Further Reading
Lee, J. 1999. What Your Doctor May Not Tell You about Premenopause. NY: Warner Books.
Ross, J. 2002. The Mood Cure. NY: Penguin Books.
Return to:
Understanding PMS and PMDD
Original Publication Date: 1/29/2007
Last Modified: 08/17/2009
Principal Author: Amy Amoroso